Todays Report: The Stemline Therapeutics Inc. (STML) Decreased to “Hold” at The Zacks Investment Research

The Stemline Therapeutics Inc. (STML) Decreased to “Hold” at The Zacks Investment Research

Stemline Therapeutics Inc. (NASDAQ:STML) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

Several other brokerages also recently issued reports on STML. Jefferies Group restated a “buy” rating and set a $23.00 price objective on shares of Stemline Therapeutics in a research report on Friday, July 22nd. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, August 23rd. Finally, Roth Capital restated a “buy” rating and set a $32.00 price objective on shares of Stemline Therapeutics in a research report on Thursday, August 25th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.50.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 1.10% on Wednesday, reaching $13.50. The company’s stock had a trading volume of 25,636 shares. Stemline Therapeutics has a 52-week low of $3.88 and a 52-week high of $14.20. The firm has a 50 day moving average of $12.22 and a 200 day moving average of $8.93. The company’s market cap is $240.92 million.

Several large investors have recently added to or reduced their stakes in STML. Candriam Luxembourg S.C.A. acquired a new stake in Stemline Therapeutics during the third quarter worth $2,783,000. Baker BROS. Advisors LP purchased a new position in shares of Stemline Therapeutics during the third quarter valued at approximately $3,612,000. Northern Trust Corp increased its position in shares of Stemline Therapeutics by 4.0% in the third quarter. Northern Trust Corp now owns 187,393 shares of the biopharmaceutical company’s stock valued at $2,029,000 after buying an additional 7,280 shares in the last quarter. Columbus Circle Investors purchased a new position in shares of Stemline Therapeutics during the third quarter valued at approximately $1,577,000. Finally, California State Teachers Retirement System increased its position in shares of Stemline Therapeutics by 0.8% in the third quarter. California State Teachers Retirement System now owns 35,649 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 300 shares in the last quarter. Institutional investors own 49.23% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Related posts

Leave a Comment